Gara Jalqabaatti › Kansarii Hafuu Seli Xiqqaa › Virginia › Arlington
Qorannoo klinikaalii Kansarii Hafuu Seli Xiqqaa Arlington, VA keessatti
Qorannoo 23 Kansarii Hafuu Seli Xiqqaa f Arlington fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Virginia Cancer Specialists - Fairfax /ID# 278298, Fairfax · Miili 11 fagaatti
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists - Fairfax /ID# 280710, Fairfax · Miili 11 fagaatti
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Inova Schar Cancer Institute Clinical Trials, Fairfax · Miili 11 fagaatti
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Site 1002, Fairfax · Miili 11 fagaatti
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · Miili 11 fagaatti
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Virginia Cancer Specialists, Fairfax · Miili 11 fagaatti
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
Namoota walitti qabaa jiraSadarkaa 1
- Next Virginia, Fairfax · Miili 11 fagaatti
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Virginia Cancer Specialists Research Institute, Fairfax · Miili 11 fagaatti
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Clinical Trial Site, Fairfax · Miili 11 fagaatti
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Virginia, Fairfax · Miili 11 fagaatti
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- NEXT Oncology Virginia, Fairfax · Miili 11 fagaatti
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- NEXT Virginia, Fairfax · Miili 11 fagaatti
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site 102, Fairfax · Miili 11 fagaatti
- Research Site 112, Fairfax · Miili 11 fagaatti
Qorannoo Kansarii Hafuu Seli Xiqqaa magaalota biroo keessatti
- Houston, TXQorannoo 26
- New York City, NYQorannoo 22
- Boston, MAQorannoo 21
- Nashville, TNQorannoo 20
- Los Angeles, CAQorannoo 20
- Orlando, FLQorannoo 15
- Dallas, TXQorannoo 13
- Cleveland, OHQorannoo 13
- Chicago, ILQorannoo 13
- St. Louis, MOQorannoo 13
- Detroit, MIQorannoo 12
- Washington, DCQorannoo 12
Qorannoo biroo Arlington keessatti
- Kansara Qara'a Non-Small CellQorannoo 104
- Kansara MetastatikiiQorannoo 53
- Kansarii ColorectalQorannoo 52
- Saree (Gosoota Hunda)Qorannoo 48
- Saree OljooQorannoo 47
- Kansarii OvariiQorannoo 46
- Dhibee QaraQorannoo 41
- Kansa EndometiriyaaliiQorannoo 39
- Kansarii PancreasQorannoo 33
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 26
- Kanisa HarkaaQorannoo 20
- Kansaar Onnee Triple-NegativeQorannoo 20
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.